The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
<i>Background and Objectives:</i> On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI AG
2021-03-01
|
| Collection: | Medicina |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/1648-9144/57/3/257 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|